http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104163870-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 |
| filingDate | 2014-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104163870-B |
| titleOfInvention | Recombinant protein of specific antagonist TNF alpha signal paths of joint targeting and application thereof |
| abstract | The invention belongs to gene engineering technology field, more particularly to a kind of recombinant protein of special antagonism TNF alpha signal paths of joint targeting and application thereof.The technical problem to be solved in the present invention provides a kind of new selection for RA treatments.The technical scheme is that recombined human progranulin is in C-terminal or N-terminal connecting joint target polypeptide NQR recombined human progranulin rPGRN NQR.Present invention also offers the carrier for expressing above-mentioned recombined human progranulin rPGRN NQR.Present invention also offers the host cell containing the carrier.Present invention also offers TNF alpha-2 antagonists.Present invention also offers the medicine for the treatment of rheumatoid arthritis.Recombined human progranulin rPGRN NQR of the present invention are a kind of very outstanding RA treatment drug candidates. |
| priorityDate | 2013-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 140.